FOR ADULTS WITH ACTIVE PsA

SIMPONI ARIA^® IS THE FIRST AND ONLY ANTI-TNFα BIOLOGIC WITH FACIT-F IN THE LABEL

ACR20 Response at Week 14 (primary endpoint): 75% of patients receiving SIMPONI ARIA^® +/- MTX achieved ACR20 response vs 22% of patients receiving placebo +/- MTX (P<0.001)^1-3

FACIT-Fatigue (FACIT-F) measures a patient’s level of fatigue and tiredness over the last 7 days through a questionnaire consisting of 13 questions.¹

Treatment with SIMPONI-ARIA^® resulted in improvement in fatigue as measured by FACIT-F²

The FACIT-F endpoint was not adjusted for multiplicity. Therefore, statistical significance has not been established.

PATIENTS WITH A ≥4-POINT IMPROVEMENT IN FATIGUE AS MEASURED BY FACIT-F

The FACIT-F endpoint was not adjusted for multiplicity. Therefore, statistical significance has not been established.

The threshold for clinically meaningful improvement when assessing fatigue using FACIT-F in clinical trials was a change of ≥4-point improvement.

^*Change from baseline in FACIT-F score is based on observed values.

^†In rheumatology, a change of 4 points in FACIT-F score was considered meaningful and has been used as response definition in the PsA population.

^‡The same patients may not have responded at each time point.

^§Although not developed for PsA, FACIT-Fatigue has been used to assess fatigue in rheumatology, and its properties have been evaluated for the PsA population.

^||Improvement from baseline in FACIT-fatigue score is based on observed values.

^¶After Week 24, patients and doctors knew that all patients were on SIMPONI ARIA^® (blinded active treatment), which may have affected the results.

NEXT: View Safety Profile in PsA: Placebo-Controlled Phase »

INFUSION EXPERIENCE

SIMPONI ARIA^® offers an efficient 30-minute infusion.

LEARN MORE

DOSING CALCULATOR

Calculate an adult patient's dose of SIMPONI ARIA^® based
on weight.

GET STARTED

ACCESS AND AFFORDABILITY

View first-line coverage rates for SIMPONI ARIA^®.